[go: up one dir, main page]

MX2022013010A - Composiciones y metodos para inhibir la expresion genica de lpa. - Google Patents

Composiciones y metodos para inhibir la expresion genica de lpa.

Info

Publication number
MX2022013010A
MX2022013010A MX2022013010A MX2022013010A MX2022013010A MX 2022013010 A MX2022013010 A MX 2022013010A MX 2022013010 A MX2022013010 A MX 2022013010A MX 2022013010 A MX2022013010 A MX 2022013010A MX 2022013010 A MX2022013010 A MX 2022013010A
Authority
MX
Mexico
Prior art keywords
lpa
gene expression
inhibiting
agents
compositions
Prior art date
Application number
MX2022013010A
Other languages
English (en)
Inventor
Darren H Wakefield
David B Rozema
David L Lewis
Aaron Almeida
Lauren J Almeida
Stacey Melquist
Steven Kanner
Vladimir S Trubetskoy
Tao Pei
Zhen Li
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of MX2022013010A publication Critical patent/MX2022013010A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen los agentes de interferencia de ARN (ARNi) y los conjugados de los agentes ARNi para inhibir la expresión del gen LPA (apo(a)). También se describen composiciones farmacéuticas que comprenden uno o más agentes de ARNi de LPA opcionalmente con uno o más agentes terapéuticos. La entrega de los agentes de ARNi de LPA descritos a las células hepáticas in vivo proporciona la inhibición de la expresión del gen LPA y el tratamiento de enfermedades cardiovasculares y cardiovasculares relacionadas.
MX2022013010A 2015-10-01 2018-03-27 Composiciones y metodos para inhibir la expresion genica de lpa. MX2022013010A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01
US201662346304P 2016-06-06 2016-06-06
US201662383221P 2016-09-02 2016-09-02

Publications (1)

Publication Number Publication Date
MX2022013010A true MX2022013010A (es) 2022-11-09

Family

ID=58424351

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003833A MX2018003833A (es) 2015-10-01 2016-09-30 Composiciones y metodos para inhibir la expresion genica de lpa.
MX2022013010A MX2022013010A (es) 2015-10-01 2018-03-27 Composiciones y metodos para inhibir la expresion genica de lpa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018003833A MX2018003833A (es) 2015-10-01 2016-09-30 Composiciones y metodos para inhibir la expresion genica de lpa.

Country Status (37)

Country Link
US (4) US9932586B2 (es)
EP (2) EP4029941A1 (es)
JP (4) JP6991966B2 (es)
KR (2) KR102728481B1 (es)
CN (1) CN108368506A (es)
AU (3) AU2016331084B2 (es)
BR (1) BR112018006489A2 (es)
CA (1) CA3000397A1 (es)
CL (1) CL2018000803A1 (es)
CO (1) CO2018003678A2 (es)
CR (1) CR20180231A (es)
CY (1) CY1125263T1 (es)
DK (1) DK3356529T3 (es)
EA (1) EA038478B1 (es)
ES (1) ES2896298T3 (es)
HR (1) HRP20211410T1 (es)
HU (1) HUE055942T2 (es)
IL (3) IL300438A (es)
JO (2) JOP20210043A1 (es)
LT (1) LT3356529T (es)
MA (1) MA43347B1 (es)
MX (2) MX2018003833A (es)
MY (1) MY195796A (es)
PE (1) PE20181139A1 (es)
PH (1) PH12018500713A1 (es)
PL (1) PL3356529T3 (es)
PT (1) PT3356529T (es)
RS (1) RS62523B1 (es)
SG (1) SG10202008530TA (es)
SI (1) SI3356529T1 (es)
SM (1) SMT202100622T1 (es)
TN (1) TN2018000094A1 (es)
TW (3) TWI836693B (es)
UA (1) UA121998C2 (es)
UY (1) UY36926A (es)
WO (1) WO2017059223A2 (es)
ZA (1) ZA202106265B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718133B2 (en) 2003-10-09 2010-05-18 3M Innovative Properties Company Multilayer processing devices and methods
NZ785880A (en) * 2016-03-07 2025-09-26 Arrowhead Pharmaceuticals Inc Targeting ligands for therapeutic compounds
JOP20170056B1 (ar) * 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
SI3607069T1 (sl) 2017-04-05 2023-02-28 Silence Therapeutics Gmbh Produkti in sestavki
JP2020526192A (ja) * 2017-07-06 2020-08-31 アローヘッド ファーマシューティカルズ インコーポレイテッド アルファ−ＥＮａＣの発現を阻害するためのＲＮＡｉ剤、および使用方法
US10597657B2 (en) * 2017-09-11 2020-03-24 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
CN111343994B (zh) * 2017-09-14 2023-11-21 箭头药业股份有限公司 用于抑制血管生成素-样3 (ANGPTL3)的表达的RNAi剂和组合物以及使用方法
AU2018346507B2 (en) 2017-10-04 2025-03-13 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
CA3079413A1 (en) * 2017-10-17 2019-04-25 Arrowhead Pharmaceuticals, Inc. Rnai agents and compositions for inhibiting expression of asialoglycoprotein receptor 1
HUE061265T2 (hu) * 2017-11-13 2023-06-28 Silence Therapeutics Gmbh Nukleinsavak LPA expressziójának gátlására sejtben
EP3483270A1 (en) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
MY209138A (en) * 2018-09-19 2025-06-24 Arrowhead Pharmaceuticals Inc Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use
CN113227372A (zh) * 2018-11-13 2021-08-06 赛伦斯治疗有限责任公司 用于抑制细胞中lpa的表达的核酸
EP3980436A4 (en) * 2019-06-06 2023-12-20 Avidity Biosciences, Inc. NUCLEIC ACID POLYPEPTIDE COMPOSITIONS AND USES THEREOF
US20220307024A1 (en) * 2019-06-17 2022-09-29 Alnylam Pharmaceuticals, Inc. Delivery of oligonucleotides to the striatum
CN112442499A (zh) * 2019-08-30 2021-03-05 恩智（广州）医药科技有限公司 一种抑制MCM7的siRNA、组合物及其应用
MX2022007005A (es) 2019-12-09 2022-08-25 Amgen Inc Construcciones de iarn y metodos para inhibir la expresion de lpa.
AU2021244329A1 (en) * 2020-03-23 2022-09-29 Amgen Inc. Monoclonal antibodies to chemically-modified nucleic acids and uses thereof
TWI886314B (zh) 2020-08-05 2025-06-11 美商戴瑟納製藥股份有限公司 抑制ｌｐａ表現之組合物及方法
US20240035029A1 (en) * 2020-10-16 2024-02-01 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
JP7798881B2 (ja) * 2020-11-05 2026-01-14 アムジェン インコーポレイテッド アテローム硬化性心血管疾患をＬＰＡ標的ＲＮＡｉ構築体により処置する方法
WO2022121959A1 (zh) * 2020-12-09 2022-06-16 纳肽得有限公司 siRNA分子及其在治疗冠状动脉疾病中的应用
WO2022136466A1 (en) 2020-12-23 2022-06-30 Argonaute RNA Limited Treatment of cardiovascular disease
EP4355756A4 (en) 2021-06-18 2025-08-13 Hongene Biotech Corp N-ACETYLGALACTOSAMINE FUNCTIONALIZED NUCLEOSIDES
JP2024532271A (ja) 2021-08-30 2024-09-05 ホンジーン バイオテック コーポレイション 官能化ｎ－アセチルガラクトサミンアナログ
JP2024531728A (ja) 2021-09-14 2024-08-29 アルゴノート アールエヌエー リミテッド 心血管疾患の処置
JP2024534508A (ja) * 2021-09-18 2024-09-20 成都心正合医▲葯▼科技有限公司 Ｌｐａ阻害剤及びその使用
EP4448540A1 (en) 2021-12-15 2024-10-23 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
CN118076738A (zh) * 2021-12-16 2024-05-24 上海拓界生物医药科技有限公司 靶向LPA的siRNA及缀合物
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
JP2025526074A (ja) * 2022-08-11 2025-08-07 エピジェニック・セラピューティクス・プライベイト・リミテッド エピトープ編集標的のための方法およびその使用
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
WO2024151937A1 (en) * 2023-01-13 2024-07-18 Eli Lilly And Company Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same
WO2024210530A1 (en) * 2023-04-03 2024-10-10 Olix Pharmaceuticals, Inc. RNAi AGENTS TARGETING LPA GENE AND USE THEREOF
CN121127587A (zh) * 2023-04-24 2025-12-12 上海京新生物医药有限公司 用于抑制LPA表达的RNAi剂及其应用
CN120035578A (zh) 2023-05-19 2025-05-23 深圳信立泰药业股份有限公司 一种磺酰胺类化合物及其制备方法和医药用途
WO2024240212A1 (zh) * 2023-05-24 2024-11-28 云合智药（苏州）生物科技有限公司 用于抑制angptl3表达的rnai剂及其应用
AU2024279456A1 (en) * 2023-05-31 2025-12-04 Arrowhead Pharmaceuticals, Inc. HEPATIC DELIVERY PLATFORMS FOR MULTIMERIC RNAi AGENT CONJUGATES AND METHODS OF USE THEREOF
AU2024280186A1 (en) 2023-05-31 2025-12-04 Tuojie Biotech (Shanghai) Co., Ltd. Dsrna targeting lpa and use thereof
DE102023115075A1 (de) * 2023-06-07 2024-12-12 B.Braun Avitum Ag Schlauchrollenpumpe
TW202530406A (zh) 2023-09-21 2025-08-01 美商Ionis製藥公司 用於抑制ｌｐａ的化合物及方法
WO2025082058A1 (zh) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 一种抑制LPA基因表达的dsRNA及其用途
CN120344664A (zh) * 2023-10-27 2025-07-18 北京安龙生物医药有限公司 靶向脂蛋白a的寡核苷酸及其用途
TW202540420A (zh) * 2023-11-15 2025-10-16 大陸商北京加科瑞康醫藥科技有限公司 用於抑制LPA的基因表現的siRNA，含其的組合物及其用途
CN120020252A (zh) * 2023-11-17 2025-05-20 纳肽得(青岛)生物医药有限公司 抑制LPA表达的siRNA及其用途
CN120098993A (zh) * 2023-12-05 2025-06-06 广东东阳光药业股份有限公司 一种新型的双链siRNA、其缀合物及其用途
CN120485189B (zh) * 2025-07-16 2025-10-17 北京悦康科创医药科技股份有限公司 靶向调控LPA基因表达的siRNA及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
DE60130583T3 (de) * 2000-12-01 2018-03-22 Europäisches Laboratorium für Molekularbiologie Kleine rns moleküle, die rns-interferenz vermitteln
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
DE602004027798D1 (de) 2003-03-12 2010-08-05 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
US20050277610A1 (en) 2004-03-15 2005-12-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
EP2061443A4 (en) 2006-08-18 2013-07-24 Arrowhead Res Corp POLYCONJUGATE FOR IN VIVO ADMINISTRATION OF POLYNUCLEOTIDES
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
KR101728655B1 (ko) 2008-12-18 2017-04-19 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
JP6137834B2 (ja) 2010-02-24 2017-05-31 アローヘッド ファーマシューティカルズ インコーポレイテッド ｓｉＲＮＡの標的化送達のための組成物
WO2011141703A1 (en) * 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
US8501930B2 (en) * 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
EP2652134B1 (en) * 2010-12-17 2017-03-01 Arrowhead Pharmaceuticals, Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
NZ611656A (en) 2010-12-29 2014-10-31 Arrowhead Res Corp In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
PH12014500214A1 (en) 2011-08-26 2019-03-22 Arrowhead Res Corporation Poly (vinyl ester) polymers for in vivo nucleic acid delivery
PT3301177T (pt) * 2011-11-18 2020-06-29 Alnylam Pharmaceuticals Inc Agentes de arni, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
CN103764153A (zh) 2012-04-18 2014-04-30 箭头研究公司 用于体内核酸递送的聚(丙烯酸酯)聚合物
PT2855500T (pt) * 2012-05-24 2020-09-24 Ionis Pharmaceuticals Inc Métodos e composições para modular a expressão de apolipoproteína(a)
US9999680B2 (en) * 2013-02-28 2018-06-19 Immunogen, Inc. Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
RS60796B1 (sr) * 2013-05-01 2020-10-30 Ionis Pharmaceuticals Inc Kompozicije i postupci za modulaciju ekspresije apolipoproteina (a)
WO2016149020A1 (en) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents
AR104754A1 (es) 2015-05-29 2017-08-09 Arrowhead Pharmaceuticals Inc Agentes de unión de tetrapéptido escindibles biológicamente
BR112018000542B1 (pt) * 2015-07-31 2023-01-24 Alnylam Pharmaceuticals, Inc Agente de ácido ribonucleico de fita dupla para inibição da expressão de transtiretina em uma célula, composição farmacêutica, uso dos anteriores, e método in vitro para inibição da expressão de transtiretina em uma célula
NZ785880A (en) 2016-03-07 2025-09-26 Arrowhead Pharmaceuticals Inc Targeting ligands for therapeutic compounds

Also Published As

Publication number Publication date
JOP20160211B1 (ar) 2021-08-17
JP2024009262A (ja) 2024-01-19
JP2021087459A (ja) 2021-06-10
AU2025242219A1 (en) 2025-10-23
SMT202100622T1 (it) 2022-01-10
KR20240162596A (ko) 2024-11-15
BR112018006489A2 (pt) 2018-10-09
IL290566B1 (en) 2023-03-01
AU2022283623A1 (en) 2023-02-02
DK3356529T3 (da) 2021-11-08
TWI836693B (zh) 2024-03-21
JP6991966B2 (ja) 2022-02-03
EP3356529A2 (en) 2018-08-08
WO2017059223A2 (en) 2017-04-06
RS62523B1 (sr) 2021-11-30
EA038478B1 (ru) 2021-09-03
IL300438A (en) 2023-04-01
ES2896298T3 (es) 2022-02-24
CO2018003678A2 (es) 2018-11-30
US20180195070A1 (en) 2018-07-12
AU2016331084A1 (en) 2018-04-19
KR20180052703A (ko) 2018-05-18
CY1125263T1 (el) 2023-03-24
PH12018500713A1 (en) 2018-10-15
AU2022283623B2 (en) 2025-07-10
CA3000397A1 (en) 2017-04-06
TWI880645B (zh) 2025-04-11
HRP20211410T1 (hr) 2021-12-24
WO2017059223A9 (en) 2017-08-17
US10662427B2 (en) 2020-05-26
PE20181139A1 (es) 2018-07-17
SG10202008530TA (en) 2020-10-29
JP2018529732A (ja) 2018-10-11
TW202449154A (zh) 2024-12-16
AU2016331084B2 (en) 2022-09-08
MA43347B1 (fr) 2021-11-30
MA43347A (fr) 2018-08-08
EP4029941A1 (en) 2022-07-20
IL258333B (en) 2022-03-01
TW201726918A (zh) 2017-08-01
EP3356529B1 (en) 2021-08-25
HUE055942T2 (hu) 2022-01-28
CL2018000803A1 (es) 2018-08-31
JP2022113835A (ja) 2022-08-04
UA121998C2 (uk) 2020-08-25
ZA202106265B (en) 2023-08-30
CN108368506A (zh) 2018-08-03
JP7442574B2 (ja) 2024-03-04
US9932586B2 (en) 2018-04-03
CR20180231A (es) 2018-05-31
TW202332769A (zh) 2023-08-16
EP3356529A4 (en) 2019-09-04
UY36926A (es) 2017-04-28
TWI784934B (zh) 2022-12-01
US20170096665A1 (en) 2017-04-06
KR102728481B1 (ko) 2024-11-12
PT3356529T (pt) 2021-11-04
US20250115907A1 (en) 2025-04-10
PL3356529T3 (pl) 2021-12-20
NZ741086A (en) 2023-11-24
IL290566A (en) 2022-04-01
SI3356529T1 (sl) 2022-01-31
IL258333A (en) 2018-05-31
NZ780687A (en) 2025-06-27
WO2017059223A3 (en) 2017-05-11
LT3356529T (lt) 2021-12-27
EA201890864A1 (ru) 2018-09-28
TN2018000094A1 (en) 2019-07-08
US20200263179A1 (en) 2020-08-20
JOP20210043A1 (ar) 2017-06-16
HK1259063A1 (en) 2019-11-22
JP7116212B2 (ja) 2022-08-09
MY195796A (en) 2023-02-21
IL290566B2 (en) 2023-07-01
MX2018003833A (es) 2018-06-18

Similar Documents

Publication Publication Date Title
MX2022013010A (es) Composiciones y metodos para inhibir la expresion genica de lpa.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ECSP20017905A (es) AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA APOLIPOPROTEÍNA C-III (APOC3)
PE20201287A1 (es) Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
UY36285A (es) Compuestos que inhiben la proteína mcl-1
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
MX2014015185A (es) Derivados deuterados de ruxolitinib.
MX375836B (es) Composiciones y métodos para inhibir la expresión del gen de alfa-1 antitripsina.
MX2019014800A (es) Agentes de iarn para la inhibicion de la expresion de alfa-enac y metodos de uso.
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
MX2014006088A (es) Biomarcadores para canceres que responden a moduladores de la actividad de hec1.
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
AR106227A1 (es) COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN GÉNICA DEL GEN DE LA APOLIPOPROTEÍNA APO(a) (LPA)
AR112754A1 (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE a-ENaC Y MÉTODOS DE USO
AR113014A1 (es) AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA APOLIPOPROTEÍNA C-III (APOC3)
AR105611A1 (es) TERAPIA ARNi PARA INFECCIÓN POR VIRUS DE HEPATITIS B